A drug previously studied for HIV and other conditions is now being tested in Alzheimer's patients for the first time. CytoDyn Inc. announced that the first patient has been dosed in a Phase 2a clinical study evaluating leronlimab as a potential treatment for Alzheimer's disease. The study is being conducted in collaboration with Weill Cornell Medicine.
Leronlimab is a CCR5 antagonist, meaning it blocks a specific receptor on immune cells. Researchers have been exploring whether blocking that receptor could have effects on neuroinflammation and disease progression in the brain. Alzheimer's disease affects millions of Americans and currently has very limited treatment options, making new research directions a focus of significant scientific interest.
The Phase 2a designation means this is an early-stage human trial. These studies are designed primarily to evaluate safety and to gather initial data on whether the drug has any measurable effect. They typically involve a smaller number of patients than later-stage trials. If results are promising, larger Phase 2b or Phase 3 trials would follow before any regulatory approval process could begin.
CytoDyn is a biopharmaceutical company that has been developing leronlimab across multiple disease areas. The collaboration with Weill Cornell Medicine brings an academic medical research institution into the study, which provides independent scientific oversight and access to clinical infrastructure.
The announcement did not include a timeline for when results from the Phase 2a study might be available, nor did it specify how many patients are enrolled in the trial. Those details are typically disclosed through clinical trial registries or subsequent company updates.
